Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted 18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern

Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted 18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern

New radiotracers for positron emission tomography imaging that target prostate-specific membrane antigen (PSMA) have emerged as important clinical tools for imaging prostate cancer (PCa). PSMA-targeted radiotracers have demonstrated high sensitivity and high specificity for detecting sites of PCa an...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yafu Yin, Channing J. Paller, Martin G. Pomper, Kenneth J. Pienta, Michael A. Gorin, Steven P. Rowe
Format:	Article
Language:	English
Published:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2019-10-01
Series:	World Journal of Nuclear Medicine
Subjects:	18f-dcfpyl positron emission tomography/computed tomography prostate cancer prostate-specific membrane vas deferens
Online Access:	http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_50_18
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
by: Marcus Edward Asokendaran, et al.
Published: (2019-07-01)

Oligometastasis to testis in prostate cancer: Role of gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography
by: Manoj Gupta, et al.
Published: (2021-03-01)

COMPUTER TOMOGRAPHY IN DIAGNOSIS OF DISEASES AND NEW FORMATIONS OF THE PROSTATE GLAND
by: D. E. Baikov, et al.
Published: (2017-07-01)

A pilot study of PSMA-targeted F-18-DCFPyL PET imaging of patients with adenoid cystic carcinoma
by: Andrew F. Voter, et al.
Published: (2025-05-01)

False-positive prostate cancer bone metastases on magnetic resonance imaging correctly classified on gallium-68-prostate-specific membrane antigen positron emission tomography computed tomography
by: Sofiullah Abubakar, et al.
Published: (2018-10-01)

Updates on controversies surrounding the staging and management of newly diagnosed localized prostate cancer using prostate-specific membrane antigen (PSMA) positron emission tomography
by: Patricia Tai, et al.
Published: (2025-07-01)

Nuclear medicine in prostate cancer: A new era for radiotracers
by: Vincenzo Cuccurullo, et al.
Published: (2018-04-01)

Port site metastasis after robotic assisted laparoscopic radical prostatectomy: Diagnosis via prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL PET/CT
by: Joon Yau Leong, et al.
Published: (2025-07-01)

The potential of generative AI with prostate-specific membrane antigen (PSMA) PET/CT: challenges and future directions
by: Islam Md Zobaer, et al.
Published: (2025-01-01)

The Performance and Role of PSMA PET Scans in Localised Prostate Cancer
by: Jianliang Liu, et al.
Published: (2025-02-01)

Fluorodeoxyglucose, sodium fluoride, and prostate-specific membrane antigen positron emission tomography studies for treatment response assessment in prostate cancer
by: Ismet Sarikaya, et al.
Published: (2018-07-01)

Can gallium-68 prostate-specific membrane antigen ligand be a potential radiotracer for renal cortical positron emission tomography imaging?
by: Ismet Sarikaya, et al.
Published: (2018-04-01)

Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review
by: Soroush Rais-Bahrami, et al.
Published: (2025-05-01)

CURRENT POSSIBILITIES OF RADIATION DIAGNOSIS OF PROSTATE CANCER
by: F. A. Kossov, et al.
Published: (2017-12-01)

Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer
by: Laura Bauersachs, et al.
Published: (2025-07-01)

Usefulness of prostate specific antigen density in detecting prostate carcinoma: A hospital-based study in patients with prostate biopsies
by: Reshmi Shrestha, et al.
Published: (2022-03-01)

Current biomarkers of prostate cancer
by: I. A. Aboian, et al.
Published: (2021-12-01)

Experience in the use of MRI-ultrasound fusion-targeted biopsy of the prostate for the diagnosis of prostate cancer
by: E. S. Nevirovich, et al.
Published: (2018-10-01)

Optimization of HIFU monotherapy for prostate cancer
by: K. V. Pozdnyakov, et al.
Published: (2022-04-01)

Geographic variability in contemporary utilization of PET imaging for prostate cancer: a medicare claims cohort study
by: Stephan M. Korn, et al.
Published: (2025-07-01)

Correlation of expression of Cyclin D1 and E-cadherin with gleason grade, serum prostate specific antigen levels and prostatic volume in prostatic carcinoma
by: C Aatirah, et al.
Published: (2023-07-01)

The impact of exercise on prostate-specific antigen and testosterone in prostate cancer: a systematic review and meta-analysis
by: Fuxun Zhang, et al.
Published: (2025-12-01)

Prostate cancer diagnosis and management: current practices in Africa a consultant-based survey
by: Marcella Derboise Christelle Biyouma, et al.
Published: (2025-03-01)

Male sexuality and the risk of developing benign prostatic hyperplasia and prostate cancer: is there a connection?
by: M. I. Kogan, et al.
Published: (2025-07-01)

Transperineal laser ablation of the prostate as a treatment for benign prostatic hyperplasia and prostate cancer: The results of a Delphi consensus project
by: Andrea Cocci, et al.
Published: (2024-04-01)

Spectrum of conditionally pathogenic microflora isolated from the prostate secret in chronic bacterial prostatitis patients
by: T. V. Tunik, et al.
Published: (2017-09-01)

The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer
by: Yeasin Ahamed, et al.
Published: (2025-08-01)

A Case Report and Literature Review of Prostatic Tuberculosis Masquerading as Prostate Cancer: A Diagnostic Challenge in a Tuberculosis-Endemic Region
by: Yonathan William, et al.
Published: (2025-05-01)

Use of a BMI-independent biomarker-based prostate cancer risk score to identify and triage individuals at risk of prostate disease
by: Joanne Watt, et al.
Published: (2025-07-01)

Neoadjuvant prostate artery embolization prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation
by: Vaseem M. Khatri, et al.
Published: (2025-11-01)

Induction of chronic prostatitis does not alter the innate contractile properties of the prostate or urethra in rats
by: Ozgu Aydogdu, et al.
Published: (2025-06-01)

DIAGNOSTIC VALUE OF DEFINITION OF FRACTIONS OF PROSTATIC SPECIFIC ANTIGEN AND PROSTATE HEALTH INDEX
by: A. S. Al-Shukri, et al.
Published: (2017-04-01)

THE PROGNOSTIC VALUE OF BASELINE PSA BLOOD IN THE TREATMENT OF PROSTATE CANCER
by: A. A. Gritskevich, et al.
Published: (2017-02-01)

Utility of positron emission tomography–computed tomography in the evaluation of fever of unknown origin in a resource-limited tropical nation
by: Sohini Das, et al.
Published: (2021-07-01)

Increased GPR35 expression is correlated with poor prognosis in prostate cancer
by: Tianyi Zhang, et al.
Published: (2025-06-01)

Multi-omic insights into mitochondrial dysfunction and prostatic disease: evidence from transcriptomics, proteomics, and methylomics
by: Binbin Gong, et al.
Published: (2025-08-01)

Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer
by: Mike Wenzel, et al.
Published: (2025-07-01)

The role of reactive oxygen species in the transformation from prostatitis to prostate cancer: a review
by: Kaihua Tang, et al.
Published: (2025-08-01)

The Rebound Effect of the COVID-19 Pandemic on Clinically Significant Prostate Cancer Diagnosis
by: Antonio Fanelli, et al.
Published: (2025-03-01)

POWER DOPPLER IMAGING IN PATIENTS WITH SUSPECTED PROSTATE CANCER
by: T. V. Shatylko, et al.
Published: (2016-09-01)